Proteome Sciences PLC (LSE:PRM) — Stock Price
Proteome Sciences PLC (LSE:PRM) is currently trading at GBX1.81 GBX, up 0.28% today. Over the past 52 weeks, shares have ranged between GBX1.28 and GBX3.60. This page tracks Proteome Sciences PLC's live share price on the LSE exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see PRM stock market capitalisation.
Proteome Sciences PLC (PRM) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Proteome Sciences PLC's daily closing share price and trading volume on the LSE exchange over the past year, giving a clear view of recent price momentum and liquidity.
Proteome Sciences PLC Income Statement — Revenue, Profit & Earnings by Year
Proteome Sciences PLC's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | GBX3.76 Million | GBX4.89 Million | GBX5.03 Million | GBX7.78 Million | GBX5.12 Million |
| Cost of Revenue | GBX4.76 Million | GBX5.05 Million | GBX3.87 Million | GBX3.01 Million | GBX2.17 Million |
| Gross Profit | GBX-1.01 Million | GBX-167.00K | GBX1.16 Million | GBX4.77 Million | GBX2.96 Million |
| Research & Development | — | GBX606.00K | GBX637.00K | GBX376.00K | GBX287.00K |
| SG&A | GBX2.58 Million | GBX3.02 Million | GBX3.27 Million | GBX2.64 Million | GBX2.33 Million |
| Total Operating Expenses | GBX1.66 Million | GBX2.11 Million | GBX2.63 Million | GBX3.28 Million | GBX2.44 Million |
| Operating Income | GBX-2.67 Million | GBX-2.27 Million | GBX-1.47 Million | GBX1.49 Million | GBX512.00K |
| EBITDA | GBX-1.74 Million | GBX-1.44 Million | GBX-986.00K | GBX1.89 Million | GBX725.00K |
| EBIT | GBX-2.67 Million | GBX-2.27 Million | GBX-1.47 Million | GBX1.49 Million | GBX512.00K |
| Interest Expense | GBX925.00K | GBX895.00K | GBX797.00K | GBX473.00K | GBX294.00K |
| Income Before Tax | GBX-3.59 Million | GBX-3.25 Million | GBX-2.42 Million | GBX1.25 Million | GBX118.00K |
| Income Tax Expense | GBX-530.00K | GBX158.00K | GBX25.00K | GBX-70.00K | GBX46.00K |
| Net Income | GBX-3.06 Million | GBX-3.41 Million | GBX-2.44 Million | GBX1.32 Million | GBX72.00K |
Proteome Sciences PLC Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Proteome Sciences PLC's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | GBX8.26 Million | GBX9.21 Million | GBX11.46 Million | GBX1.51 Trillion | GBX1.38 Trillion |
| Total Current Assets | GBX2.07 Million | GBX2.59 Million | GBX4.16 Million | GBX252.89 Billion | GBX240.31 Billion |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | — | — | — | — | — |
| Net Receivables | GBX754.00K | GBX509.00K | GBX1.05 Million | GBX1.57 Million | GBX927.00K |
| Inventory | GBX537.00K | GBX732.00K | GBX837.00K | GBX901.00K | GBX1.09 Million |
| Property, Plant & Equipment | — | — | — | — | GBX1.27 Million |
| Goodwill | GBX4.22 Million | GBX4.22 Million | GBX4.22 Million | GBX3.91 Billion | GBX3.89 Billion |
| Total Liabilities | GBX17.79 Million | GBX15.72 Million | GBX14.52 Million | GBX1.44 Trillion | GBX1.31 Trillion |
| Total Current Liabilities | GBX16.57 Million | GBX14.01 Million | GBX12.47 Million | GBX4.62 Billion | GBX4.17 Billion |
| Long-term Debt | GBX0.00 | GBX250.00K | GBX0.00 | — | — |
| Net Debt | GBX14.99 Million | GBX13.39 Million | GBX11.45 Million | GBX-112.98 Billion | GBX-101.73 Billion |
| Total Stockholder Equity | GBX-9.53 Million | GBX-6.52 Million | GBX-3.07 Million | GBX68.29 Billion | GBX69.05 Billion |
| Retained Earnings | GBX-68.76 Million | GBX-76.35 Million | GBX-72.94 Million | GBX52.83 Billion | GBX50.49 Billion |
Proteome Sciences PLC Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Proteome Sciences PLC generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | GBX-46.00K | GBX-826.00K | GBX-481.00K | GBX2.14 Million | GBX793.00K |
| Capital Expenditures | GBX97.00K | GBX224.00K | GBX237.00K | GBX1.75 Billion | GBX1.72 Billion |
| Free Cash Flow | GBX-143.00K | GBX-1.05 Million | GBX-718.00K | GBX2.14 Billion | GBX8.80 Billion |
| Investing Cash Flow | GBX-97.00K | GBX-224.00K | GBX-424.00K | GBX-21.67 Billion | GBX4.27 Billion |
| Financing Cash Flow | GBX-204.00K | GBX151.00K | GBX-1.06 Million | GBX-209.00K | GBX-400.00K |
| Dividends Paid | — | — | GBX2.19 Billion | GBX1.93 Billion | GBX1.36 Billion |
| Stock-Based Compensation | GBX18.00K | GBX40.00K | GBX218.00K | GBX303.00K | GBX570.00K |
| Depreciation | GBX926.00K | GBX837.00K | GBX484.00K | GBX284.00K | GBX213.00K |
| Change in Cash | GBX-347.00K | GBX-899.00K | GBX-1.97 Million | GBX19.58 Billion | GBX49.06 Billion |
Proteome Sciences PLC Earnings History — EPS Actual vs. Analyst Estimates
Track Proteome Sciences PLC's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Apr 08, 2026 | — | — | — |
| Sep 11, 2025 | -0.01 | — | — |
| Apr 18, 2025 | 0.00 | 0.00 | — |
| Apr 04, 2023 | 0.00 | 0.00 | — |
| Aug 04, 2022 | 0.00 | 0.00 | — |
| Mar 31, 2022 | 0.00 | 0.00 | — |
| Jul 29, 2021 | 0.00 | 0.00 | — |
| Apr 12, 2021 | 0.00 | 0.00 | — |